Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | JAX:10000009 |
Name | Squamous Cell Carcinoma of Unknown Primary |
Definition | Squamous cell carcinoma for which the tissue of origin cannot be determined |
Source | Genomenon (a custom term added that does not correspond to an existing term in the disease ontology) |
Alt Ids | |
Path | Squamous Cell Carcinoma of Unknown Primary |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
MLH1 negative | Pembrolizumab | Squamous Cell Carcinoma of Unknown Primary | sensitive | detail... |
PMS2 negative | Pembrolizumab | Squamous Cell Carcinoma of Unknown Primary | sensitive | detail... |
MSH2 negative | Pembrolizumab | Squamous Cell Carcinoma of Unknown Primary | sensitive | detail... |
MSH6 negative | Pembrolizumab | Squamous Cell Carcinoma of Unknown Primary | sensitive | detail... |
RET fusion | Selpercatinib | Squamous Cell Carcinoma of Unknown Primary | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | Squamous Cell Carcinoma of Unknown Primary | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06640725 | Phase II | Cetuximab + Cisplatin + Docetaxel Carboplatin + Cetuximab + Docetaxel Avelumab + Cetuximab | Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N (TATIANA) | Recruiting | FRA | 0 |